BusinessCocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C VirusBy Nasdaq OMXApr 3, 2018, 12:01 PM UTC
